Tissue Regenix Group plc (LON:TRX – Get Free Report)’s share price traded up 17.6% during trading on Friday . The company traded as high as GBX 29.40 ($0.39) and last traded at GBX 29.40 ($0.39). 134,613 shares were traded during mid-day trading, an increase of 143% from the average session volume of 55,417 shares. The stock had previously closed at GBX 25 ($0.34).
Tissue Regenix Group Stock Performance
The stock has a fifty day simple moving average of GBX 30.63 and a two-hundred day simple moving average of GBX 40.45. The company has a debt-to-equity ratio of 31.16, a quick ratio of 2.36 and a current ratio of 4.03. The stock has a market cap of £26.96 million, a PE ratio of -30.87 and a beta of 1.61.
Tissue Regenix Group Company Profile
Tissue Regenix is a leading medical device company in regenerative medicine. The Company’s patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient’s body that can be used to repair diseased or damaged body structures.
Further Reading
- Five stocks we like better than Tissue Regenix Group
- Large Cap Stock Definition and How to Invest
- The Utilities Sector Is Heating Up—Don’t Miss the Breakout
- Growth Stocks: What They Are, Examples and How to Invest
- How Goldman Sachs Earnings Help You Strategize Your Portfolio
- With Risk Tolerance, One Size Does Not Fit All
- 3 Catalysts Driving Plug Power’s Turnaround Case
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.
